The stock’s institutional ownership stands at 17.80%. Exact Sciences reported revenue of $21.2 million for the quarter, beating estimates of $18.54 million. The offering was surged to 8,500,000 shares from the before reported offering of 7,000,000 shares due to market demand. Gofen & Glossberg LLC IL bought a new stake in Exact Sciences Corp. during the second quarter worth approximately $130,000. Moreover, Thompson Investment Management Inc. has 1.09% invested in the company for 772,250 shares.
Advertisement
06/16/2016 – EXACT Sciences Corporation was upgraded to “buy” by analysts at Craig-Hallum.
The company’s weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, feeble growth in its earnings per share, generally disappointing historical performance in the stock itself and weak operating cash flow. US Bancorp DE raised its position in Exact Sciences Corp.by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 648,520 shares of the company’s stock valued at $4,371,000 after buying an additional 28,116 shares during the period.
According to Zacks Investment Research, “EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer”. (NASDAQ:EXAS) traded down 1.85% during midday trading on Wednesday, reaching $15.91.
The stock’s price switched up 33.31% 20-Days Simple Moving Average, added 73.00% from 50-Days Simple Moving Average and positively 109.95% from 200 Days Simple Moving Average.
The Company has 97.25 million shares outstanding and 95.43 million shares were floated in market.
CRM is ahead its 52-week low with 55.80%and going down from its 52-week high price with -2.99%.
Exact Sciences Corporation (EXAS) today declared the upsizing and pricing of its formerly declared underwritten public offering of common stock.
While Looking at the Earnings Estimates of the company, The Average Earnings Estimate for the Current Fiscal quarter is measured as -$0.44 by 13 analysts. 1 Month Ago, shares have been suggested as “BUY” from “5” brokerage firms and recommended as “Strong Buy” by “0” brokerage firms. 2 researchers gave long-term targets for the earning per share of the firm over a period of three to five years. The business’s revenue for the quarter was up 161.7% compared to the same quarter past year.
The share price of CSX Corporation (NASDAQ:CSX) plunged -7.98% for the year.
Several other research analysts have also weighed in on EXAS. Benchmark Co. boosted their target price on Exact Sciences Corp. from $9.00 to $14.00 and gave the stock a “hold” rating in a research report on Wednesday.
On Thursday, Shares of EXACT Sciences Corporation (NASDAQ:EXAS) gained 2.97% to $17.32.
05/05/2015 – EXACT Sciences Corporation had its “mkt outperform” rating reiterated by analysts at JMP Securities.
Advertisement
Exact Sciences said it will sell 8.5 million shares of stock at $15.50 a share, in a secondary offering through underwriters Jefferies and Robert W. Baird & Co., with Canaccord Genuity as co-manager.
